Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 6/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019515 | 0.88 | HTT (0.41) | HTTMAP3K5SMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL4569246 | 0.82 | NUDT1 (0.41) | HTTMAP3K5SMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL4572193 | 0.82 | HTT (0.51) | HTTMAP3K5SMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL2623139 | 0.79 | MAPT (0.55) | HTTSMN1; SMN2NPC1TSHRRAB9A | |
| SCHEMBL21814339 | 0.78 | HTT (0.58) | HTTMAP3K5SMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL5019519 | 0.76 | HSD17B10 (0.39) | HTTMAP3K5SMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL4569237 | 0.76 | JAK3 (0.35) | LRRK2CSF1RJAK3 | |
| SCHEMBL29100435 | 0.73 | LRRK2 (0.41) | HTTMAP3K5SMN1; SMN2NCOA1NCOA3 | |
| Dimethyladenine SCHEMBL152593 | 0.72 | LRRK2 (0.52) | HTTMAP3K5ADORA2ALRRK2ADORA3 | |
| SCHEMBL29804812 | 0.72 | HTT (0.36) | HTTMAP3K5SMN1; SMN2NCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388183-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9315505-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2014-10-02 | — | — | US | disclosed |
| US-8785454-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HTT 823/4885MAP3K5 53/4885SMN1; SMN2 1464/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HTT 823/4885MAP3K5 53/4885SMN1; SMN2 1464/4885 |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, AKT3, PIK3CD | HTT 1246/4885MAP3K5 88/4885SMN1; SMN2 2594/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HTT 996/4885MAP3K5 52/4885SMN1; SMN2 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.